Jacob Laubach's guest appearances

Jacob Laubach

HealthTree Podcast for Multiple Myeloma

HemOnc for the Internist

Johns Hopkins

Stephen Russell

Adam Cohen

David Siegel

Mike Thompson

Beth Israel

Damian Green

Sarah Cannon

Keith Stewart

Mark Newman

Paul Richardson

Stephen Harding

Kenneth Anderson

Vincent Rajkumar

Thomas Martin

OwlTail

Multiple myeloma is one of the most fascinating hematological malignancies and I couldn't think of a better way to kick start the "Liquid tumor series". Today, we have with us Dr Jacob Laubach, author of the section on "Multiple myeloma-clinical features and diagnosis" on UpToDate, one of the most referenced and trusted information sources for all internists. Join us in our conversation about the pathophysiology, typical and atypical presentations and the core principles of diagnosis of multiple myeloma.

"LIQUID TUMORS SERIES"- Multiple Myeloma Part I- Approach and Diagnosis with Dr Jacob Laubach

Dana Farber

While immunotherapy approaches expand, proteasome inhibitors remain a staple therapy of multiple myeloma. Learn why they work, how they differ, how the new oral version (Ninlaro) is bringing greater convenience to the clinic, why they continue to be developed and how they are being used in quad combinations with immunotherapies to fight myeloma. Dr. Jacob Laubach shares how they differ, who they work best for (and don't), when they should be used as maintenance therapy and how a new gene may give us clues into who will respond and who will not. Thanks to our episode sponsor, Takeda Oncology.

While immunotherapy approaches expand, proteasome inhibitors remain a staple therapy of multiple myeloma. Learn why they work, how they differ, how the new oral version (Ninlaro) is bringing greater convenience to the clinic, why they continue to be developed and how they are being used in quad combinations with immunotherapies to fight myeloma. Dr. Jacob Laubach shares how they differ, who they work best for (and don't), when they should be used as maintenance therapy and how a new gene may give us clues into who will respond and who will not. <br><br>Thanks to our episode sponsor, Takeda Oncology.

Myeloma Crowd Radio: Dr. Jacob Laubach, MD, MPP, Dana Farber Cancer Institute